Sarepta Therapeutics Inc.Find Ratings Reports
SAREPTA THERAPEUTICS INC's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. SAREPTA THERAPEUTICS INC is extremely liquid. Currently, the Quick Ratio is 12.55 which clearly shows the ability to cover any short-term cash needs. SRPT managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 134.40% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||57.28||5.42|
|Net Income ($mil)||-24.0||-88.45|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||1079.06||328.54|
|Total Assets ($mil)||1307.96||424.1|
|Total Debt ($mil)||431.05||16.15|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||-36.27||-1560.45|
|Return on Assets||-3.87||-63.01|
|Return on Equity||-6.42||-79.37|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||64.79||54.76|
|Div / share||0.0||0.0|
|Book value / share||12.18||6.15|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1400403.0||1619421.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.42 indicates a significant premium versus the S&P 500 average of 3.22 and a significant discount versus the industry average of 14.28. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SAREPTA THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|SRPT NM||Peers 38.97||SRPT NM||Peers 29.91|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SRPT's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
SRPT's P/CF is negative making the measure meaningless.
|SRPT NM||Peers 16.09||SRPT NA||Peers 0.34|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SRPT's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SRPT 7.42||Peers 14.28||SRPT 85.35||Peers 1.44|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SRPT is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SRPT is expected to have an earnings growth rate that significantly exceeds its peers.
|SRPT 37.86||Peers 61.63||SRPT 2751.57||Peers 327.41|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SRPT is trading at a significant discount to its industry on this measurement.
Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.
SRPT has a sales growth rate that significantly exceeds its peers.